Editor-in-Chief’s Commentary: Gene Penetrance, Therapeutic Targets, and Regulatory Science Stephen P. Spielberg Commentary 30 December 2013 Pages: 289 - 290
Associate Editor’s Commentary: Measuring Responsibility Peter J. Pitts Commentary 30 December 2013 Pages: 291 - 293
Summary of DIA Workshop on Co-Development of Personalized Medicine and In Vitro Diagnostic Companion Devices Lisa Palladino KimJeffrey N. StuartJames A. Boiani DIA Workshops 30 December 2013 Pages: 294 - 298
Transparency at the EMA: More Evidence Is Needed Ragnar E. Löfstedt Regulatory Science 30 December 2013 Pages: 299 - 300
Achieving a Culture of Quality in Pharmaceutical Biostatistics: One Approach to Achieving Quality Deliverables Michael J. Fiola Biostatistics 30 December 2013 Pages: 301 - 305
Public Health Innovation: Biopharmaceuticals Lost in Translation? Nader D. HalimJohn J. Doyle Public Health 30 December 2013 Pages: 306 - 311
Translation and Labeling in Europe: Thoughts on the Process and Organization for Efficient Translation Sourcing Matthias HeynRaun Kupiec Global Perspectives 30 December 2013 Pages: 312 - 326
Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs Yauba SaiduDario De AngelisAnne Marie Georges Global Perspectives 30 December 2013 Pages: 327 - 335
Impact of In-Pharmacy Education on Patients’ Knowledge and Attitudes About Clinical Trials Kenneth A. Getz Patient Perspectives 30 December 2013 Pages: 336 - 340
Chronically Ill Czech Patients’ Beliefs About Medicines: The Psychometric Properties and Factor Structure of the BMQ-CZ Petra MatoulkovaIva Selke KrulichovaRob Horne Patient Perspectives 30 December 2013 Pages: 341 - 348
Defining Patient-Centricity: Opportunities, Challenges, and Implications for Clinical Care and Research Dennis A. RobbinsFrederick A. CurroChester H. Fox Patient Perspectives 30 December 2013 Pages: 349 - 355
Training New-Hire Medical Information Specialists in the Pharmaceutical Industry: A Benchmarking Survey Juhi JaisinghaniShrina Patel Drug Information 30 December 2013 Pages: 356 - 362
Optimizing Drug Development Programs: Type 2 Diabetes Case Study Zoran AntonijevicMartin KimberKlas Bergenheim Drug Development 30 December 2013 Pages: 363 - 374
Drug Development in the 21st Century: The Synergy of Public, Private, and International Collaboration Frank E. CastyMatthew S. Wieman Drug Development 30 December 2013 Pages: 375 - 383
